TL;DR: The Centers for Medicare & Medicaid Services modified NCD 200, its National Coverage Determination for evoked response tests, effective March 7, 2026. The policy confirms Medicare coverage for brain stem evoked response and visual evoked response tests — but the policy does not list specific CPT codes, which creates real documentation work for your billing team.
CMS modified NCD 200, the governing National Coverage Determination for evoked response tests under Medicare, with a modification date of March 7, 2026. The policy covers brain stem evoked response and visual evoked response procedures — tests that measure brain responses to repetitive visual, auditory click, or other stimuli. No specific CPT or HCPCS codes are enumerated in the policy document itself, which means your team needs to cross-reference the Claims Processing Instructions to confirm which codes map to this NCD before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Evoked Response Tests |
| Policy Code | NCD 200 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Neurology, Audiology, Ophthalmology, Neurodiagnostics, Physical Medicine & Rehabilitation |
| Key Action | Confirm your CPT codes for brain stem and visual evoked response tests align with CMS Claims Processing Instructions before submitting claims under NCD 200 post-March 7, 2026 |
CMS Evoked Response Tests Coverage Criteria and Medical Necessity Requirements 2026
NCD 200 is the National Coverage Determination governing Medicare coverage of evoked response tests — specifically brain stem evoked response (BSER) and visual evoked response (VER) tests. CMS's position is direct: these procedures are "generally accepted as safe and effective diagnostic tools," and Medicare program payment may be made for them.
That language matters for medical necessity documentation. "Generally accepted as safe and effective" is CMS's standard threshold for coverage, and it means you don't need to fight the experimental designation battle on these tests. What you do need is documentation tying the test to a specific clinical indication — whether that's suspected multiple sclerosis, acoustic neuroma workup, intraoperative monitoring, or another diagnosis your physician is pursuing.
The coverage policy does not impose prior authorization requirements at the NCD level, which is worth knowing. That said, individual Medicare Administrative Contractors (MACs) can — and do — issue Local Coverage Determinations (LCDs) that layer additional criteria on top of NCDs. Check with your MAC before assuming the NCD's broad coverage language is the whole story for your region.
One thing this modification does not do: resolve ambiguity about which specific procedures are in scope. The policy broadly references "evoked response tests" as a category, including brain stem evoked response and visual evoked response tests. Somatosensory evoked potentials and other evoked response modalities aren't explicitly named. That gap is worth flagging to your compliance officer if your practice bills a range of neurodiagnostic procedures.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Brain stem evoked response tests | Covered | Not specified in NCD 200 — see Claims Processing Instructions | Medical necessity documentation required |
| Visual evoked response tests | Covered | Not specified in NCD 200 — see Claims Processing Instructions | Medical necessity documentation required |
| Evoked response tests generally (repetitive visual, auditory click, or other stimuli) | Covered | Not specified in NCD 200 — see Claims Processing Instructions | MAC LCDs may impose additional criteria |
CMS Evoked Response Tests Billing Guidelines and Action Items 2026
The policy language is permissive — CMS says these tests are covered and program payment may be made. But "may be made" is not a guarantee, and the absence of enumerated codes in the NCD creates real billing risk if your team isn't aligned on the right CPT codes.
Here's what to do before claims go out under this updated policy:
| # | Action Item |
|---|---|
| 1 | Pull the CMS Claims Processing Instructions cross-referenced in NCD 200. The NCD itself lists no codes, but the Claims Processing Instructions are where the operative billing detail lives. Obtain that document and confirm which CPT codes your MAC recognizes for brain stem evoked response and visual evoked response tests under this NCD. Do this before March 7, 2026. |
| 2 | Audit your charge capture for evoked response procedures. Verify that the CPT codes your practice currently bills for BSER and VER tests are correctly mapped and not flagged for any existing claim denial patterns. If you're seeing denials on these codes, the policy modification is a good trigger to investigate root cause — it may be a documentation gap, not a coverage issue. |
| 3 | Check your MAC's LCD for additional medical necessity criteria. NCD 200 is permissive, but your MAC may have a Local Coverage Determination that specifies qualifying diagnoses, documentation requirements, or frequency limits. Reimbursement can be denied at the MAC level even when the NCD allows coverage. |
| 4 | Review your ICD-10-CM linkage on claim submissions. Evoked response tests are ordered for specific clinical indications — demyelinating disease, posterior fossa tumors, unexplained vision loss, neonatal hearing screening, intraoperative monitoring. Make sure your ICD-10 codes on the claim reflect the documented clinical reason for the test. A mismatch between the test ordered and the diagnosis on the claim is one of the fastest routes to a claim denial. |
| 5 | Flag this for your compliance officer if your practice bills a broad range of evoked response modalities. NCD 200 names brain stem and visual evoked response tests explicitly. If your neurodiagnostics team also bills somatosensory evoked potentials or other modalities, confirm whether those fall under NCD 200 or a different coverage determination. Don't assume the NCD's general language covers every modality your team performs. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Evoked Response Tests Under NCD 200
The policy data for NCD 200 does not enumerate specific CPT, HCPCS, or ICD-10 codes. This is not a minor detail — it means your billing team cannot rely on the NCD document itself to confirm which codes are in scope.
What the Policy Says About Codes
NCD 200 explicitly cross-references Claims Processing Instructions for billing guidance. That is where CMS expects you to find the operative code-level detail. Contact your Medicare Administrative Contractor or access the CMS Claims Processing Instructions through the Medicare Claims Processing Manual to identify the relevant codes for brain stem evoked response and visual evoked response tests in your region.
Why This Matters for Claim Submission
Billing without confirming the correct CPT codes against your MAC's Claims Processing Instructions is a denial risk. The NCD establishes that these tests are covered — it does not tell you how to submit the claim. Those are two different things, and conflating them is how clean claims turn into rework.
If your billing consultant or RCM team hasn't already mapped your evoked response CPT codes to this NCD, that's the first call to make before March 7, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.